On October 2, 2025, Perspective Therapeutics announced via Globe Newswire that the first patient was treated with its lead radiopharmaceutical [212Pb]PSV359 in the second cohort of its Phase 1/2a dose‑finding trial. The announcement was made from Seattle and confirms the company’s progress in evaluating the safety and preliminary anti‑tumor activity of the agent in patients with solid tumors expressing fibroblast activation protein‑α (FAP‑α).
The second‑cohort enrollment follows the initial cohort that began in April 2025, marking a key milestone in the clinical development program. By expanding to a second cohort, Perspective Therapeutics is advancing the dose‑range exploration and gathering additional safety data that will inform future trial design and potential regulatory submissions.
Perspective Therapeutics, formerly a Cesium‑131 brachytherapy provider, has repositioned itself as a clinical‑stage radiopharmaceutical company focused on targeted alpha therapies. The company’s continued progress in the PSV359 program supports its broader strategy to deliver high‑energy alpha‑particle treatments for solid tumors and underscores its commitment to advancing the platform toward regulatory approval.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.